FDAsafety guidance54% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (melanoma) as Immunocore.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Immune-Mobilizing T-cell Receptors
- Sub-indication
- Melanoma
Related signal: Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma